Related Experiment Videos
p53 accumulation in benign breast biopsy specimens
M Younes1, R M Lebovitz, K E Bommer
1Department of Pathology, Baylor College of Medicine, Houston, TX 77030.
Human Pathology
|February 1, 1995
Summary
p53 protein accumulation is not a reliable indicator of breast cancer malignancy. While found in some benign breast lesions, it does not significantly predict future cancer development in these cases.
Area of Science:
- Oncology
- Pathology
- Biomarker Research
Background:
- Previous studies suggested p53 accumulation is rare in benign breast lesions.
- Investigators proposed p53 immunoreactivity could indicate malignancy or premalignancy.
Purpose of the Study:
- To investigate the prevalence of p53 immunoreactivity in benign and malignant breast lesions.
- To determine if p53 status in benign lesions predicts future breast carcinoma development.
Main Methods:
- Immunohistochemical (IHC) staining using anti-p53 antibody BP-53-12.
- Analysis of 271 breast biopsy specimens (23 malignant, 248 benign).
- Long-term follow-up for 48 patients with benign biopsy results.
Main Results:
- Positive p53 nuclear staining was found in 30% of malignant lesions and 16% of benign lesions.
- 30% of fibroadenomas (benign) showed p53 positivity.
- No significant difference in subsequent breast carcinoma development between p53-positive (12%) and p53-negative (7%) benign cases.
Conclusions:
- p53 immunoreactivity alone is insufficient for diagnosing breast cancer malignancy.
- p53 status in benign breast lesions does not identify patients at significantly higher risk for developing breast carcinoma.